

# **Advances in the Management of Stage III Non-Small Cell Lung Cancer: Focus on Evolving Approaches with Immune Checkpoint Inhibitors**

## ***PowerPak Podcast***

### **REFERENCES**

1. Albain K, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trial. *Lancet* 2009; 374: 379-386.
2. Van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. *J Natl Cancer Inst* 2007; 99: 442-450.
3. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *NEJM* 2017; 377: 1919-1929.
4. National Comprehensive Cancer Network. Non-small cell lung cancer version 2.2020-December 23, 2019.
5. Soria JC, Vansteenkiste YO, Reungwetwattana T, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *NEJM* 2018; 378: 113-125.
6. Peters S, Camidge R, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *NEJM* 2017; 377: 829-838.
7. Ribas A. Tumor immunotherapy directed at PD-1. *NEJM* 2012; 366(26): 2517-2519.
8. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *NEJM* 2016; 375: 1823-1833.
9. Durm GA, Althouse SK, Sadiq AA, et al. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. *J Clin Oncol* 2018; 36(15\_suppl): 8500.
10. Peters S, Felip E, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-the ETOP NICOLOAS trial. *Lung cancer* 2019; 133: 83-87.
11. Lin SH, Lin Y, Mok I, et al. Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer. *J Clin Oncol* 2019; 37(15\_suppl): 8512.
12. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities version 1.2020-December 16, 2019.